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Background: Individuals with diabetes have been found previously to be at increased risk of non-traumatic fracture.
However, it is unclear if these individuals are being identified and treated for osteoporosis.
Methods: 7753 Canadians over 50 years of age were followed prospectively for 10 years. 606/7753 (7.8%) of had
diabetes; 98 were insulin-dependent and 508 were not. Using a cox proportional hazards model, we assessed the
association between diabetes status and incident non-traumatic fracture. Using logistic regression we identified
factors associated with bisphosphonate use over the 10 year period of study.
Results: Mean (SD) age of participants was 66.7(9.4) years and 72% were female. Those with diabetes had
higher BMD T-scores at baseline, with a mean (SD) femoral neck T-Score of −0.97 (1.06), compared to −1.24
(0.99) in the general cohort. The adjusted hazard ratio (HR) for incident non-traumatic fracture in individuals
with insulin-dependent diabetes over the 10 year study period was 2.50 (95% confidence interval [CI] 1.60,
3.90; p < 0.001). Despite this increased fracture rate, individuals with diabetes (insulin-dependent or non-insulin-
dependent) were less likely to be on bisphosphonate therapy at any point over 10 years of prospective follow up
compared to other CaMos subjects (odds ratio [OR]: 0.59; 95% CI 0.46-0.75, p < 0.001).
Conclusions: Despite the increased risk of non-traumatic fracture associated with insulin-dependent diabetes,
we that found individuals with diabetes are less likely to be treated with a bisphosphonate than those without
diabetes. These findings point to a possible care gap in the treatment of non-traumatic fractures in individuals
with diabetes in Canada.
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Osteoporosis is a common condition in Canada, affect-
ing 21% of women and 5% of men over the age of 50 years
[1]. Multiple observational studies have been performed
around the world showing that diabetes (both type 1 and
type 2) is associated with an increased risk of non-
traumatic fracture. Non-traumatic, or “fragility” fractures
are fractures that occur with minimal trauma, such as a
fall from standing height or less [2,3]. A prior fracture is* Correspondence: Lisaann.Fraser@sjhc.london.on.ca
1Department of Medicine, University of Western Ontario, London, Ontario,
Canada
4Division of Endocrinology and Metabolism, St. Joseph’s Hospital, 268
Grosvenor Street, London N6A 4 V2, Ontario, Canada
Full list of author information is available at the end of the article
© 2014 Fraser et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the oran important risk factor for having future fractures [4].
Recent meta-analyses indicate an increased relative risk
for hip fracture in type 2 diabetics of 1.4 to 1.7 and in type
1 diabetics of 6.3 to 6.9 [5,6]. Other skeletal sites have also
been found to be at increased risk of fracture in the dia-
betic population [7,8].
In the only Canada-wide study performed to-date,
Hanley et al. examined prevalent vertebral deformities,
as measured by spinal radiographs, and found no signifi-
cant increase in individuals with type 1 diabetes (OR: 1.24;
95% CI 0.68,2.51) or type 2 diabetes (OR: 0.91; 0.67,1.25)
[9]. However, no study to-date has prospectively examined
non-traumatic clinical fractures (both vertebral and non-
vertebral) in the diabetic population in Canada. Similarly,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ies looking at osteoporosis treatment rates amongst the
diabetic population. Given the osteoporosis treatment
“care gap” that has been identified in the general popula-
tion [10,11], we hypothesize that an even greater care gap
exists within the diabetic population. The primary object-
ive of this study was to evaluate the relationship between
diabetes and incident non-traumatic fracture, with the
secondary aim of evaluating associated bisphosphonate
treatment over a 10 year period, in a large population-
based longitudinal cohort study, including men and women
with insulin-dependent and non-insulin-dependent diabetes
in Canada.
Methods
The Canadian Multicenter Osteoporosis Study (CaMos)
is an on-going population-based cohort study looking at
osteoporosis and fracture risk in community dwelling
Canadians. Baseline questionnaires were completed in
1995–1997. The institutional review boards of all sites
participating in CaMos approved the study and informed
consent was obtained from all participants. The study
has been described in detail elsewhere [12], but areas
relevant to this study are summarized below. Data from
years 0 through 10 were used for this study and all
women and men aged 50 years or older were included in
the analyses.
Review Boards that approved the CaMos study:
McGill University Health Centres-Montreal General
Hospital Research Ethics Committee.
Conjoint Health Research Ethics Board of the Faculty
of Medicine, University of Calgary.
St. Joseph’s Healthcare, McMaster University Research
Ethics Board.
Queen’s University Research Ethics Board.
Memorial University of Newfoundland, Human
Investigations Committee.
University of Saskatchewan Advisory Committee on
Ethics in Human Experimentation.
St. Michael’s Hospital Research Ethics Board (Toronto).
Capital Health Research Ethics Board (Halifax).
The University of British Columbia Clinical Research
Ethics Board.
Centre hospitalier de l’Université Laval Comite
d’Ethique de la Recherche Clinique.
Study participants
Participants were recruited from within 50-kilometers of
one of 9 study centers across Canada (St. John’s, Halifax,
Quebec City, Toronto, Hamilton, Kingston, Saskatoon,
Calgary and Vancouver). 9,423 individuals (6,539 females
and 2,884 males) aged 25 years and older, representing
an age-stratified-, sex-, and region-specific sample, wereidentified from lists of random telephone numbers over
an 18 month period.
Data collection
An interviewer-administered questionnaire was per-
formed at baseline, and at years 3, 5 and 10 of the study.
Diabetes status was captured in the baseline question-
naire where participants were asked if they had insulin
dependent diabetes mellitus (IDDM) or non-insulin
dependent diabetes mellitus (NIDDM). All past medical
history was by patient report. At baseline, year 5, and 10,
bone mineral density (BMD) testing was performed. At
years 1, 2, 4, 6, 7, 8 and 9, a two-page questionnaire was
mailed to participants which included questions about
bone-related medications. All participant medications
were documented in detail during the interviewer-
administered questionnaires.
Bone mineral density and fractures
BMD of the hip and lumbar spine (L1-L4) were measured
by dual-energy X-ray absorptiometry (DXA) using Hologic
QDR 1000, 2000, 4500 or Lunar DPX machines. Densi-
tometers were calibrated daily, and quality assurance was
performed following a standard daily and weekly schedule.
Initially, cross-calibration of the machines was performed
at the nine centers using a European Spine Phantom.
After this, the Bone Fide phantom was performed at base-
line and in the year of every examination. Reports indicat-
ing bone density (g/cm2), and T-scores were sent to each
participant, a physician named by the participant, or both
depending on the centre [13]. All clinically recognized
non-traumatic fractures were included in the analysis (hip
fractures, clinical vertebral fractures, non-vertebral frac-
tures). Any fracture associated with trauma or described
as a fall from more than standing height was excluded. At
baseline, previous fractures were obtained by self-report,
but subsequent fractures were reported by patients and
confirmed by medical or radiographic reports.
Statistical analysis
All analyses were restricted to CaMos participants ≥
50 years of age. Baseline characteristics were described
using mean (standard deviation) for continuous variables
and count (percentage) for nominal variables. The pri-
mary objective of determining the association between
diabetes (insulin-dependent and non-insulin dependent)
and incident non-traumatic fracture was examined using
a Cox Proportional Hazards regression model, adjusting
for age, gender, baseline femoral neck T-score, history of
previous non-traumatic fracture, body mass index (BMI),
bisphosphonate use and past use of corticosteroids. Age was
divided into 10-year categories (50–59, 60–69, 70–79, ≥80).
Age 50–59 was used as the reference category in the
analyses. Diabetes was defined as either insulin-dependent
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betes mellitus (NIDDM). BMD was divided into femoral
neck T-scores of ≥ −1.0, <−1.0 to > −2.5, and ≤ −2.5. BMI
was divided into categories including: <18.5, ≥ 18.5
to <25, ≥25 to <30, ≥30 to <35, and ≥ 35. Bisphospho-
nate use (any of: alendronate, clodronate, etidronate,
pamidronate, risedronate, and zoledronic acid) at any
time point over the 10 year study was included. Past
corticosteroid use included ever daily use of IV or oral
corticosteroids for at least one month. All independent
variables adjusted for in the model were selected be-
cause they are risk factors that have previously been
identified as having important associations with fracture
risk. Proportional hazard assumptions were tested using
Schoenfeld residual test. Logistic regression modeling
was used to determine factors associated with bisphos-
phonate use. “Ever bisphosphonate use” (ie. patient re-
ported being on a bisphosphonate at any time point
during the 10 years studied) was the dependent variable
and diabetes status, age, gender, femoral neck T-score,
rheumatoid arthritis, family history of osteoporosis, and
history of non-traumatic fracture at baseline, were covari-
ates. Sensitivity analysis using multiple imputation [14]
was performed for missing data to assess the robustness
of the model assuming the data are missing at random.
The criterion for statistical significance was set at alpha =
0.05. We used the Hosmer and Lemeshow test to assess
goodness-of-fit of logistic regression. Cox proportional
hazards modelling and Schoenfeld residual testing were
performed using SAS 9.2 (Cary, NC). Descriptive analysis,
logistic regression modeling, and multiple imputation
were performed using IBM SPSS version 19 (Ireland).
Results
Characteristics of the CaMos population over 50 years of
age (n = 7753) and of participants with insulin-dependentTable 1 Baseline characteristics of all CaMos participants ove
All CaMos partic
>50 yrs (n = 77
Age (years); mean (SD) 66.7 (9.4)
Gender (female) 71.8%
Femoral neck BMD T-score; mean (SD) −1.24 (0.99)
Caucasian 95.5%
Fracture at baseline (n;%) 2133 (27.5)
BMI; mean (SD) 27.1 (4.78)
Years since diagnosis of diabetes; mean;(SD) N/A
Cigarette use;* n (%) 4163 (53.7)
Corticosteroid use;† n(%) 415 (4.4)
Alcohol use (per wk); mean (SD) 2.88 (5.85)
*ever use daily for > 6 months.
†oral or IV, ever use daily for > 1 month.
SD: standard deviation, BMD: bone mineral density, BMI: body mass index.diabetes (n = 98) and non-insulin-dependent diabetes (n =
508) have been described previously and are shown in
Table 1 [15]. Most baseline characteristics were similar be-
tween all groups. The diabetic groups however, had higher
BMD values than the general CaMos population (Table 2).
Despite these higher values, individuals with diabetes were
more likely to have had a non-traumatic fracture at baseline
(39% of IDDM and 29% of NIDDM compared to 27% of
the general CaMos population). Individuals with IDDM re-
ported a longer duration of diabetes, 15 compared to
10 years in those with NIDDM.
Incident fractures occurred in 1098 non-diabetic indi-
viduals, with the site of first incident fracture being the
hip in 142 individuals and vertebrae in 117 individuals.
Among those with diabetes, 73 individuals sustained one
or more incident fractures over the 10 year period, 21
individuals with IDDM and 52 with NIDDM. Of these,
hip was the site of first incident fracture in 2 individuals
with IDDM and 10 individuals with NIDDM. Clinical
vertebral fracture accounted for first incident fracture in
3 participants with IDDM and 5 with NIDDM. The ad-
justed hazard ratio (HR) for incident non-traumatic frac-
ture in individuals with insulin-dependent diabetes over
the 10 year study period was 2.5 (95% CI 1.60, 3.90; p <
0.001) (Figure 1). Other variables associated with an in-
creased risk of fracture included: female gender, history
of prior fragility fracture, increased BMI, older age, lower
femoral neck T-score, corticosteroid use and bisphos-
phonate use (Table 3). Non-insulin-dependent diabetes
was not found to be associated with increased fracture
risk, HR: 1.02, 95%CI 0.77-1.35, p = 0.869. Statistical
testing showed the proportional hazards assumption was
not violated. Individuals with diabetes were less likely to
be on bisphosphonate therapy during the 10 year study
period compared to other CaMos subjects (OR: 0.68;




diabetes (n = 98)
Non-insulin-dependent
diabetes (n = 508)
68.0 (9.0) 69.4 (8.8)
64.3% 65.7%
−0.97 (1.17) −0.97 (1.04)
93.9% 94.3%
38 (38.8) 146 (28.7)
29.73 (5.45) 29.06 (5.24)
15.4 (11.28) 9.64 (9.60)
54 (55.1) 280 (55.1)
12 (12.24) 33 (6.50)
1.97 (5.45) 2.27 (6.79)
Table 2 Baseline bone mineral density values, and proportion of individuals on bisphosphonates at baseline, in CaMos
participants with and without diabetes, by BMD Category
Femoral neck T-score No diabetes BP use Insulin-dependent diabetes BP use Non-insulin-dependent diabetes BP use
> − 1.0 44.4% 0.2% 44.9% 0.0% 51.5% 0.0%
−1.0 to −2.5 48.3% 1.9% 48.7% 2.6% 43.2% 3.2%
<−2.5 7.3% 6.5% 6.4% 20% 5.3% 8.7%
BP: Bisphosphonate.
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reported bisphosphonate use during CaMOs, whereas 6
individuals (28.6%) with IDDM who sustained an inci-
dent fracture and 16 individuals (30.8%) with NIDDM
and incident fracture reported use. After multiple imput-
ation was performed for the variables: rheumatoid arth-
ritis, family history of osteoporosis and femoral neck
BMD; the relationship strengthened (OR: 0.59; 95% CI
0.46, 0.75; p < 0.001) (Table 4). Other variables associ-
ated with decreased likelihood of bisphosphonate use
were older age and increased femoral neck T-score. Vari-
ables associated with increased bisphosphonate use in-
cluded: rheumatoid arthritis, family history of osteoporosis,
female gender, and history of non-traumatic fracture. When
insulin-dependent and non-insulin-dependent diabetes and
bisphosphonate use was examined, the results were not sta-
tistically significant prior to multiple imputation. However,
after multiple imputation for variables listed above, non-P-value from the log-rank test
Figure 1 Kaplan-Meier curve showing unadjusted fragility fracture freinsulin-dependent diabetes was found to be associated with
decreased use of bisphosphonates (OR: 0.59; 95% CI 0.45,
0.78, p < 0.001), as was insulin-dependent diabetes (OR:
0.53; 95% CI 0.29, 0.95; p = 0.034) as shown in Figure 2.
When the diabetic subgroup was examined, similar risk fac-
tors (steroid use, age, female gender, lower BMD, and past
fracture) were associated with bisphosphonate use.Discussion
In our analysis, we found that Canadians with insulin-
dependent diabetes are more likely to sustain an incident
non-traumatic fracture than other Canadians over 50 years
of age. Despite this increased risk, Canadian diabetics in
CaMos (both insulin-dependent and non-insulin-dependent)
were 42% less likely than non-diabetics to be treated with a
bisphosphonate (first line therapy for prevention and treat-
ment of fragility fractures) over the 10 year study period;P<0.001
e survival by diabetes status.
Table 3 Variables associated with risk of incident non-traumatic fracture over 10 years (multivariate analysis)
Variable Hazard ratio 95% Confidence interval Significance (p-value)
Diabetes status
No diabetes reference
Non-insulin-dependent diabetes mellitus 1.02 0.77-1.35 0.864
Insulin-dependent diabetes mellitus 2.50 1.60-3.90 <0.001
Gender
Male reference
Female 1.54 1.30-1.82 <0.001
Age (years)
50-59 reference
60-69 0.95 0.80-1.13 0.551
70-79 1.40 1.17-1.67 <0.001
≥ 80 1.69 1.30-2.19 <0.001
Body mass index
18.5≤ BMI <25 reference
BMI < 18.5 0.82 0.50-1.37 0.451
25 ≤ BMI <30 1.09 0.94-1.26 0.235
30 ≤ BMI < 35 1.28 1.06-1.54 0.011
BMI≥ 35 1.35 1.02-1.80 0.037
Femoral neck BMD T-score (per SD increase) 0.69 0.64-0.76 <0.001
BMD≥ −1.0 reference
−2.5 < BMD < −1.0 1.59 1.35-1.88 <0.001
BMD≤ −2.5 2.56 2.04-3.21 <0.001
Previous history of fracture
No reference
Yes 1.58 1.39-1.79 <0.001
Corticosteroid use*
No reference
Yes 1.35 1.07-1.69 0.010
Bisphosphonate use (ever use over the 10 year study)
No reference
Yes 1.56 1.36-1.79 <0.001
*ever use daily for > 6 months.
Table 4 Variables associated with bisphosphonate use over the 10 year study period (after multiple imputation)
Variable Odds ratio 95% Confidence interval P-value
Diabetes 0.59 0.46-0.75 <0.001
Previous non-traumatic fracture 1.20 1.06-1.36 0.004
Age (per year) 0.99 0.98-0.99 <0.001
Femoral neck T-score (per SD increase) 0.39 0.36-0.42 <0.001
Rheumatoid arthritis 1.28 1.03-1.59 0.029
Family history of osteoporosis 1.24 1.06-1.44 0.008
Female gender 3.00 2.59-3.47 <0.001
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Figure 2 CaMos participants on bisphosphonate therapy with at any time during a 10 year follow-up period.
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Canadians with diabetes.
The diabetic groups in CaMos had higher BMD values
than the general CaMos population. This finding is simi-
lar to other studies which have shown higher BMD
values in type 2 diabetics, likely on the basis of elevated
BMI which is a risk factor for developing type 2 diabetes
[6,16,17]. This difference in BMI was also evident in the
CaMos population (BMI of 27 vs. 29 in diabetic partici-
pants). The higher bone density values however did not
protect the participants with diabetes from fracturing.
At study baseline, we found an increased history of
non-traumatic fractures amongst all diabetics in CaMos,
this is in-keeping with previous literature showing this
population to be at elevated fracture risk [5,6]. Looking
prospectively, we found an increased risk of incident
non-traumatic fracture in diabetics on insulin, but we
did not demonstrate an increased risk in diabetics not
on insulin. In Canada, information about fracture risk in
those with diabetes has not been abundant. The only
study to-date, also performed in the CaMos population,
focused on prevalent vertebral deformities by radiograph
and showed no increased risk in type 1 or type 2 dia-
betes [9]. Our study shows an increase in clinical non-
traumatic fractures, at any body site, in individuals with
insulin-dependent diabetes at a national level. These
findings support previous, province-wide studies, show-
ing increased risk of hip fracture, as well as other osteo-
porotic fractures, in type 2 diabetics [18,19]. Similar toour findings, studies done in other countries have shown
insulin use further increases the risk of fragility fractures
in individuals with diabetes, perhaps by acting as a
marker of disease severity [20-22]. Other explanations
for the association between insulin use and fracture in-
clude increased duration of type 2 diabetes, and the in-
clusion of individuals with type 1 diabetes [20]. Glycemic
control was not assessed in CaMos. It is not clear if our
finding of no increased risk of fracture in non-insulin-
dependent diabetics in CaMos relates to a lack of statis-
tical power needed to demonstrate a more subtle risk
increase in this population, or if this indeed signifies no in-
creased risk in this group. Given that we found those with
NIDDM had an increased prevalence of fragility fractures
at our study baseline (compared to the non-diabetic popu-
lation) and that previous studies have consistently re-
ported an increased fracture risk in this population, we
suspect a power issue is an important contributor to our
findings [5,6]. Our study was not designed to identify the
cause of increased fracture risk in diabetics; multiple dif-
ferent pathological mechanisms have been reported in the
literature in the past [23,24]. We did not have access to
measures of glycemic control, and therefore did not exam-
ine its influence on fracture risk.
We found that, despite having increased rates of non-
traumatic fractures, individuals with diabetes were less
likely to receive treatment with a bisphosphonate than
other CaMos participants. To our knowledge, this care-
gap has not been identified in the diabetic population
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well known that a large care gap exists, with many pa-
tients not being diagnosed or treated for their osteopor-
osis. This care-gap has been documented both in Canada
and internationally [25,26]. Within the general CaMos
population there have been reports of a care-gap in men
and women with fragility fractures; approximately half of
women experiencing a new fragility fracture were found
to not be treated with a bone-specific medication [10] and
over 90% of men were untreated [11]. Considering osteo-
porosis treatment rates within the CaMos population are
low, our findings of an even larger care-gap amongst those
with diabetes within CaMos suggests a dire situation for
these patients. Moreover, we found that those with IDDM
were the most likely to have had a fracture in the past and
were at higher risk of having an incident fracture over the
10 year study period, yet were the least likely to receive
treatment with a bisphosphonate over the 10 years of the
study. Although large randomized control trials proving
the efficacy of bisphosphonate therapy for fracture pre-
vention in the setting of diabetes are lacking, a large obser-
vational study and a sub-group analysis of diabetic
participants in the Fracture Intervention Trial have
found that the improvement in BMD and the decrease
in fracture risk associated with bisphosphonate therapy
is not altered by the diagnosis of diabetes. Similarly, the
tolerability of Alendronate has been found to be no dif-
ferent in diabetic vs. non-diabetic women [27,28]. There
are no accepted theories as to why a diabetes-osteoporosis
care gap exists above the level of the baseline care-gap in
the general population. One possibility may be the higher
BMD values typically found in individuals with type 2 dia-
betes. Traditionally, most clinicians have used BMD scores
to diagnose and make treatment decisions around osteo-
porosis. This bias is reflected in past osteoporosis treat-
ment guidelines [29]. Although newer guidelines focus
more on fracture risk assessment, and less on BMD alone,
many clinicians still rely heavily on BMD when making
treatment decisions. It is therefore possible that the nor-
mal or elevated BMD values that are typically seen in type
2 diabetics make clinicians less likely to suspect, or treat,
osteoporosis. This highlights the need for education and
knowledge dissemination to diabetic practitioners about
the link between diabetes and fracture.
This study has several strengths including the large
population-based sample, prospective design allowing
10 years of follow-up, inclusion of both men and
women, detailed fracture data, and the ability to differ-
entiate between insulin-dependent and non-insulin-
dependent diabetes. There are however several limitations
to this study. All the CaMos questionnaires depended on
patient reporting (subject to recall bias and misunder-
standing), therefore the incidence of certain classically
underdiagnosed conditions (such as hyperglycemia) islikely underestimated. Similarly, individuals who were not
diabetic at study baseline but became so during the course
of the study, or diabetics who became insulin-dependent
later over the 10 year study, were not captured. However,
bias from undiagnosed diabetes (or insulin use) would be
expected to decrease the effect sizes found. All fractures
included in the analyses were clinical fractures; morpho-
metric vertebral fractures were not included. The CaMos
population is mostly of Caucasian ethnicity and therefore
results cannot be extrapolated to other race groups. Thia-
zolidinediones, implicated in increasing fracture risk
[30,31], were not included in our analysis because no
CaMos participants were on one of these medications at
study baseline.
We had originally hoped to perform this study with
diabetes broken down into type 1 and type 2, rather than
IDDM and NIDDM, as the pathophysiology and epi-
demiology of skeletal fragility is different in type 1 vs.
type 2 diabetes [23,24]. However, upon examination of
the self-reported age of diagnosis of “type 1 diabetes” in
the CaMos baseline questionnaire we found that only 10
individuals (9.6% of self-reported insulin-dependent dia-
betics) were under the age of 30 years when they were
diagnosed with diabetes. This led us to suspect that this
group consists mostly of type 2 diabetics who are insulin-
dependent (relative insulin deficiency) rather than type 1
diabetics (absolute insulin deficiency). Supporting this is
the high baseline BMI and BMD values found in both dia-
betic groups, which are more typical of type 2 diabetes
than type 1 [6]. In the past, diabetes was often divided into
“insulin-dependent diabetes” and “insulin-independent”
diabetes; terms that are not generally used in the medical
community today [32]. However, this often leads to confu-
sion amongst people with diabetes who obtained their dia-
betes education and diagnosis when these terms were
commonplace. We therefore decided to report our results
as IDDM and NIDDM, as we questioned the accuracy of
the type1/type 2 classification.
Conclusions
In summary, we found that Canadians with insulin-
dependent diabetes mellitus were more likely than non-
diabetics to sustain a non-traumatic fracture over a 10 year
period. Despite this increased risk, diabetics are less likely
to receive fracture prevention therapy with a bisphospho-
nate. Clinicians that treat individuals with diabetes (espe-
cially those treated with insulin) should be taught to
incorporate fracture prevention into the current list of
interventions they offer to diabetic patients. Future studies
are needed to clarify if individuals with non-insulin-
dependent diabetes are at increased fracture risk, to valid-
ate fracture risk assessment tools within the diabetic
population and to test fracture prevention strategies and
therapies specifically in the diabetic population.
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